No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes

Markus Walter, Thomas Kaupper, Kerstin Adler, Johannes Foersch, Ezio Bonifacio, Anette-G Ziegler, Markus Walter, Thomas Kaupper, Kerstin Adler, Johannes Foersch, Ezio Bonifacio, Anette-G Ziegler

Abstract

Objective: To determine whether daily intake of 1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] is safe and improves beta-cell function in patients with recently diagnosed type 1 diabetes.

Research design and methods: Safety was assessed in an open study of 25 patients aged 18-39 years with recent-onset type 1 diabetes who received 0.25 microg 1,25(OH)(2)D(3) daily for 9 months. An additional 40 patients were randomly assigned to 0.25 microg 1,25(OH)(2)D(3) or placebo daily for 9 months and followed for a total of 18 months for safety, beta-cell function, insulin requirement, and glycemic control.

Results: Safety assessment showed values in the normal range in nearly all patients, regardless of whether they received 1,25(OH)(2)D(3) or placebo. No differences in AUC C-peptide, peak C-peptide, and fasting C-peptide after a mixed-meal tolerance test between the treatment and placebo groups were observed at 9 and 18 months after study entry, with approximately 40% loss for each parameter over the 18-month period. A1C and daily insulin requirement were similar between treatment and placebo groups throughout the study follow-up period.

Conclusions: Treatment with 1,25(OH)(2)D(3) at a daily dose of 0.25 microg was safe but did not reduce loss of beta-cell function.

Trial registration: ClinicalTrials.gov NCT00960635.

Figures

Figure 1
Figure 1
Flow of participants. A: Participation in the open study designed to assess safety of 1,25(OH)2D3 (n = 25). B: Random assignment into the phase II, randomized, double-blind, placebo-controlled study to assess efficacy of study drug (n = 22 study drug, n = 18 placebo).
Figure 2
Figure 2
Safety parameters. Plasma calcium concentrations (A) and 24-h urinary calcium excretion values (B) for patients who received study drug (n = 47, ■) and patients who received placebo (n = 18, □) over 18 months of follow-up. Data are means ± SEM. The reference calcium plasma levels (2.1–2.6 mmol/l) and urine secretion (<10 mmol/24 h) are indicated by the dotted line. VitD3, 1α,25-dihydroxyvitamin D3.
Figure 3
Figure 3
Efficacy parameters. Fasting (A) and AUC C-peptide after mixed-meal stimulation (B), mean A1C (C), and mean insulin requirement per kilogram body weight (D) in the 1,25(OH)2D3 treatment group (■) and the placebo group (□). Data are means ± SEM. VitD3, 1α,25-dihydroxyvitamin D3.

References

    1. Atkinson MA, Eisenbarth GS: Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358: 221–229
    1. Staeva-Vieira T, Peakman M, von Herrath M: Translational mini-review series on type 1 diabetes: immune-based therapeutic approaches for type 1 diabetes. Clin Exp Immunol 2007; 148: 17–31
    1. Vitamin D supplement in early childhood and risk for type I (insulin-dependent) diabetes mellitus. The Eurodiab Substudy 2 Study Group. Diabetologia 1999; 42: 51–54
    1. Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM: Intake of vitamin D and risk of type 1 diabetes; a birth-cohort study. Lancet 2001; 358: 1500–1503
    1. Zipitis CS, Akobeng AK: Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child 2008; 93: 512–517
    1. Baumgartl HJ, Standl E, Schmidt-Gayk H, Kolb HJ, Janka HU, Ziegler AG: Changes of vitamin D3 serum concentrations at the onset of immune-mediated type 1 (insulin-dependent) diabetes mellitus. Diabetes Res 1991; 16: 145–148
    1. Bierschenk L, Alexander J, Wasserfall C, Haller M, Schatz D, Atkinson M: Vitamin D levels in subjects with and without type 1 diabetes residing in a solar rich environment. Diabetes Care 2009; 32: 1977–1979
    1. D'Ambrosio D, Cippitelli M, Cocciolo MG, Mazzeo D, Di Lucia P, Lang R, Sinigaglia F, Panina-Bordignon P: Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-κB downregulation in transcriptional repression of the p40 gene. J Clin Invest 1998; 101: 252–262
    1. Piemonti L, Monti P, Sironi M, Fraticelli P, Leone BE, Dal Cin E, Allavena P, Di Carlo V: Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 2000; 164: 4443–4451
    1. Penna G, Adorini L: 1α,25-Dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000; 164: 2405–2411
    1. Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R: Dendritic cell modulation by 1α,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 6800–6805
    1. Penna G, Amuchastegui S, Giarratana N, Daniel KC, Vulcano M, Sozzani S, Adorini L: 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol 2007; 178: 145–153
    1. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O'Garra A: 1α,25-Dihydroxyvitamin D3 has a direct effect on naive CD4+ T cells to enhance the development of Th2 cells. J Immunol 2001; 167: 4974–4980
    1. Mathieu C, Gysemans C, Giulietti A, Bouillon R: Vitamin D and diabetes. Diabetologia 2005; 48: 1247–1257
    1. Teegarden D, Donkin SS: Vitamin D: emerging new roles in insulin sensitivity. Nutr Res Rev 2009; 22: 82–92
    1. Gulseth HL, Gjelstad IM, Tierney AC, Lovegrove J, Defoort C, Blaak EE, Lopez-Miranda J, Kiec-Wilk B, Risérus U, Roche HM, Drevon CA, Birkeland KI: Serum vitamin D concentration does not predict insulin action or secretion in European subjects with the metabolic syndrome. Diabetes Care 2010; 33: 923–925
    1. Pitocco D, Crinò A, Di Stasio E, Manfrini S, Guglielmi C, Spera S, Anguissola GB, Visalli N, Suraci C, Matteoli MC, Patera IP, Cavallo MG, Bizzarri C, Pozzilli P. IMDIAB Group. The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset type 1 diabetes (IMDIAB XI). Diabet Med 2006; 23: 920–923
    1. Achenbach P, Lampasona V, Landherr U, Koczwara K, Krause S, Grallert H, Winkler C, Pflüger M, Illig T, Bonifacio E, Ziegler AG: Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia 2009; 52: 1881–1888
    1. Gysemans CA, Cardozo AK, Callewaert H, Giulietti A, Hulshagen L, Bouillon R, Eizirik DL, Mathieu C: 1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice. Endocrinology 2005; 146: 1956–1964
    1. Stene LC, Joner G: Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study. Am J Clin Nutr 2003; 78: 1128–1134
    1. Li X, Liao L, Yan X, Huang G, Lin J, Lei M, Wang X, Zhou Z: Protective effects of 1-α-hydroxyvitamin D3 on residual β-cell function in patients with adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev 2009; 25: 411–416
    1. Walter M, Philotheou A, Bonnici F, Ziegler AG, Jimenez R: No effect of the altered peptide ligand NBI-6024 on β-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care 2009; 32: 2036–2040
    1. van Halteren AG, van Etten E, de Jong EC, Bouillon R, Roep BO, Mathieu C: Redirection of human autoreactive T-cells upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D3. Diabetes 2002; 51: 2119–2125
    1. Gysemans C, Van Etten E, Overbergh L, Verstuyf A, Waer M, Bouillon R, Mathieu C: Treatment of autoimmune diabetes recurrence in non-obese diabetic mice by mouse interferon-beta in combination with an analogue of 1α,25-dihydroxyvitamin-D3. Clin Exp Immunol 2002; 128: 213–220
    1. Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L: A 1α,25- dihydroxyvitamin D3 analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002; 51: 1367–1374

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner